Inify Laboratories, a pioneering laboratory service specializing in cancer diagnostics, has introduced a groundbreaking approach that revolutionizes the way cancer is detected and reported. With a focus on optimizing internal laboratory systems and enhancing customer interaction, Inify Laboratories has experienced a continuous influx of patient samples for diagnosis.
Since opening its first laboratory in June, Inify Laboratories has been analyzing prostate biopsies on a daily basis. The feedback from customers, particularly urologists and other stakeholders, has been overwhelmingly positive. The growing interest in their services is a testament to the increasing awareness of Inify Laboratories.
What sets Inify Laboratories apart is its remarkably short response time of no more than five days. Additionally, the laboratory prides itself on providing high-quality diagnostic reports that have been developed in collaboration with experienced urologists. These reports are designed to be graphic and structured, making it easier for healthcare professionals to interpret them and ultimately increasing patient safety. The urologist clinics that send prostate biopsies to Inify Laboratories have expressed high satisfaction with both the diagnostic accuracy and the swift response times.
One of the greatest challenges in cancer diagnosis is the long and unpredictable waiting times for investigations within the healthcare system. Inify Laboratories, however, is well-positioned to address this issue by offering fast and reliable diagnostics of the highest quality to patients regardless of their geographical location.
By leveraging state-of-the-art technology, Inify Laboratories has developed a fully digital, standardized, and AI-supported workflow within pathology. Initially focusing on prostate diagnostics, this innovative concept can be easily scaled and extended to other types of cancer diagnoses.
Inify Laboratories provides a comprehensive range of services that encompass the entire chain of sample handling, from logistics to sample preparation to reporting by a pathologist either from Inify Laboratories or the customer’s own organization. These reports are augmented by the company’s own AI technology, which has been proven to deliver world-leading accuracy through clinical studies. To ensure optimal workflow management, Inify Laboratories has implemented a tailor-made process control system.
The company, which was established as an independent entity in 2022 following a spin-off from ContextVision, brings with it 40 years of expertise in digital imaging for medical applications. Currently listed on Euronext Growth Oslo under the ticker INIFY, Inify Laboratories is now prepared to offer its diagnostic services to healthcare systems on a broader scale.
In conclusion, Inify Laboratories has transformed cancer diagnostics by providing rapid and precise reports that are highly valued by healthcare professionals. With its advanced technology and commitment to optimizing the diagnostic process, Inify Laboratories is set to make a significant impact in the field of cancer diagnosis.
